Several new crown pneumonia vaccines have been included in emergency use! Vaccine giants plummet

In the past two days, four institutions, including Beijing Wantai Biopharmaceutical Co., Ltd., Beijing Shenzhou Cell Biotechnology Group Co., Ltd., Clover Biopharmaceutical Co., Ltd., and West China Hospital of Sichuan University, have successively disclosed to the public that the new crown vaccine developed by them has been included in the list. Emergency use. Affected by this, on December 5, the stock price of Zhifei Bio, the “first vaccine stock” with a market value of more than 130 billion yuan, fell 3.6%, and CanSino fell 8.84%. | Related reading (China Fund News)

Living in a corner with a lone crane

Now all parts of the country are adjusting the epidemic prevention and control policies. With the relaxation of policies, the responsibility for how to protect them falls on the individual and each family. However, the vaccination rate of the elderly population in my country is still very low at this stage. In the reality that severe illness and death mostly occur in the elderly, increasing the vaccination rate of the elderly is the top priority. This may be the reason why various vaccines have been on the market recently, including the more convenient nasal spray vaccine. It is more convenient to vaccinate at any time, but it is regrettable that the mRNA vaccine, which has been confirmed to have a positive effect on reducing the rate of severe illness in foreign countries and Hong Kong, has not been introduced to the mainland. Faced with the complex epidemic situation, this There is still room for improvement.

This article is reproduced from: https://www.fortunechina.com/jingxuan/25039.htm
This site is only for collection, and the copyright belongs to the original author.